Matches in SemOpenAlex for { <https://semopenalex.org/work/W3087953478> ?p ?o ?g. }
Showing items 1 to 58 of
58
with 100 items per page.
- W3087953478 endingPage "S715" @default.
- W3087953478 startingPage "S715" @default.
- W3087953478 abstract "Immune checkpoint inhibitors (ICI) have a unique mechanism of action that differs from chemotherapy. Despite the poor correlation between ORR and overall survival (OS), 12-month OS (OS12) ratio is a good intermediate surrogate for OS at trial level. We aimed to develop and validate a model using ORR as a predictor for OS12 in ICI trials. We performed an electronic search to identify eligible studies. Randomized controlled trials (RCTs) reported between January 2020-June 2019 formed the model development dataset. Correlation between ORR and OS12 were examined both at trial and ICI arm levels. Using the ICI arm data, a linear regression model was fitted using the ordinary least-squares approach, adjusting for tumour types, with ORR as a predictor for OS12. We then extracted data from an independent dataset of RCTs and single-arm ICI studies, reported from June 2019 to Jan 2020, to validate the performance of our prediction model. We identified 63 eligible trials, with 78 ICI treatment arms (58 RCTs, 20 single-arm). Thirteen trials were doublet ICI studies. The tumours types were predominantly non-small cell lung cancer (30%) and melanoma (13%). Other main tumours types included gastric/oesophageal (10%), renal cell (9%), head and neck squamous cell (8%), urothelial carcinoma (8%) and others (17%). Fifty ICI arms (from 43 RCTs) formed the model development dataset. The validation dataset comprised of 28 ICI arms (8 RCTs, 20 single arm studies). At arm level, the correlation between ORR and OS12 within ICI arms was strong, r=0.80. Complete response rate correlates poorly with OS12 (r= 0.50). The ORR-OS12 prediction model was OS12 = (1.012324 x ORR) + 0.3006825 + (0 x melanoma) + (0.0021079 x NSCLC) – (0.038521 x other tumors). When this model was applied in the validation dataset, the fitted line of scatterplot of ORR-predicted OS12 revealed close calibration with the observed OS12, r= 0.63. At trial level, the correlation between ORR risk ratio and OS HR was poor, r=0.58. Our prediction model using ORR can be used to predict for OS12 in early phase ICI trials, regardless of tumour type, overcoming the issue of poor correlation between ORR and OS. This may help support decisions for phase III testing based on ORR in phase II trials of ICI." @default.
- W3087953478 created "2020-10-01" @default.
- W3087953478 creator A5003569285 @default.
- W3087953478 creator A5025018030 @default.
- W3087953478 creator A5026520995 @default.
- W3087953478 creator A5040043914 @default.
- W3087953478 creator A5052465499 @default.
- W3087953478 creator A5082470573 @default.
- W3087953478 date "2020-09-01" @default.
- W3087953478 modified "2023-09-26" @default.
- W3087953478 title "1042P Objective response rate as an intermediate surrogate endpoint to predict overall survival at 12 months" @default.
- W3087953478 doi "https://doi.org/10.1016/j.annonc.2020.08.1162" @default.
- W3087953478 hasPublicationYear "2020" @default.
- W3087953478 type Work @default.
- W3087953478 sameAs 3087953478 @default.
- W3087953478 citedByCount "0" @default.
- W3087953478 crossrefType "journal-article" @default.
- W3087953478 hasAuthorship W3087953478A5003569285 @default.
- W3087953478 hasAuthorship W3087953478A5025018030 @default.
- W3087953478 hasAuthorship W3087953478A5026520995 @default.
- W3087953478 hasAuthorship W3087953478A5040043914 @default.
- W3087953478 hasAuthorship W3087953478A5052465499 @default.
- W3087953478 hasAuthorship W3087953478A5082470573 @default.
- W3087953478 hasBestOaLocation W30879534781 @default.
- W3087953478 hasConcept C126322002 @default.
- W3087953478 hasConcept C141341695 @default.
- W3087953478 hasConcept C143998085 @default.
- W3087953478 hasConcept C168563851 @default.
- W3087953478 hasConcept C203092338 @default.
- W3087953478 hasConcept C535046627 @default.
- W3087953478 hasConcept C71924100 @default.
- W3087953478 hasConceptScore W3087953478C126322002 @default.
- W3087953478 hasConceptScore W3087953478C141341695 @default.
- W3087953478 hasConceptScore W3087953478C143998085 @default.
- W3087953478 hasConceptScore W3087953478C168563851 @default.
- W3087953478 hasConceptScore W3087953478C203092338 @default.
- W3087953478 hasConceptScore W3087953478C535046627 @default.
- W3087953478 hasConceptScore W3087953478C71924100 @default.
- W3087953478 hasLocation W30879534781 @default.
- W3087953478 hasOpenAccess W3087953478 @default.
- W3087953478 hasPrimaryLocation W30879534781 @default.
- W3087953478 hasRelatedWork W1852785632 @default.
- W3087953478 hasRelatedWork W2089903975 @default.
- W3087953478 hasRelatedWork W2169374891 @default.
- W3087953478 hasRelatedWork W2297790284 @default.
- W3087953478 hasRelatedWork W2959603226 @default.
- W3087953478 hasRelatedWork W3025555446 @default.
- W3087953478 hasRelatedWork W3080304190 @default.
- W3087953478 hasRelatedWork W3089163820 @default.
- W3087953478 hasRelatedWork W4282918911 @default.
- W3087953478 hasRelatedWork W4283740305 @default.
- W3087953478 hasVolume "31" @default.
- W3087953478 isParatext "false" @default.
- W3087953478 isRetracted "false" @default.
- W3087953478 magId "3087953478" @default.
- W3087953478 workType "article" @default.